

=> d his

(FILE 'HOME' ENTERED AT 10:11:44 ON 21 JUL 2005)

FILE 'HCAPLUS' ENTERED AT 10:12:00 ON 21 JUL 2005

L1 1 (US2004096519 OR US6680073)/PN OR US99-128604#/AP, PRN  
E TARBET B/AU  
L2 59 E4-6  
L3 1 L2 AND ONYCHO?  
L4 1 L1 OR L3

FILE 'REGISTRY' ENTERED AT 10:14:30 ON 21 JUL 2005

FILE 'HCAPLUS' ENTERED AT 10:14:32 ON 21 JUL 2005

L5 TRA L4 1- RN : 10 TERMS

FILE 'REGISTRY' ENTERED AT 10:14:32 ON 21 JUL 2005

L6 10 SEA L5

FILE 'WPIX' ENTERED AT 10:14:35 ON 21 JUL 2005

L7 2 (US2004096519 OR US6680073)/PN OR US99-128604#/AP, PRN  
E TARBET B/AU  
L8 29 E3-5  
L9 2 L8 AND ONYCH?  
L10 2 L7 OR L9

=> b hcap

FILE 'HCAPLUS' ENTERED AT 10:15:50 ON 21 JUL 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Jul 2005 VOL 143 ISS 4

FILE LAST UPDATED: 20 Jul 2005 (20050720/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all 14

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:54242 HCAPLUS  
DN 140:99596  
ED Entered STN: 22 Jan 2004  
TI Composition and method for the treatment of onychomycosis in animals  
IN Tarbet, Bryon J.  
PA USA  
SO U.S., 4 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
IC ICM A01N059-20

Search done by Noble Jarrell

INCL 424630000; 424405000; 424406000; 424613000; 424616000; 424631000;  
424638000; 424642000; 424641000; 424646000

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1, 5

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6680073	B1	20040120	US 2000-545486	20000410 <--
US 2004096519	A1	20040520	US 2003-706708	20031111 <--
PRAI US 1999-128604P	P	19990408	<--	
US 2000-545486	A3	20000410		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6680073	ICM	A01N059-20
	INCL	424630000; 424405000; 424406000; 424613000; 424616000; 424631000; 424638000; 424642000; 424641000; 424646000
US 6680073	NCL	424/630.000; 424/405.000; 424/406.000; 424/613.000; 424/616.000; 424/631.000; 424/638.000; 424/641.000; 424/642.000; 424/646.000; 424/648.000; 514/159.000; 514/165.000; 514/731.000
	ECLA	A61K031/30; A61K033/40 <--
US 2004096519	NCL	424/638.000; 424/616.000; 514/355.000; 514/423.000
	ECLA	A61K031/30; A61K033/40 <--

OS MARPAT 140:99596

AB This invention relates to a composition and method for the treatment of white line disease, including ailments such as **Onychomycosis**, sporotichosis, hoof rot, jungle rot, pseudallecheria boydii, scopulariopsis or athletes foot. The composition of the present invention is useful for the treatment of fungal infections such as **Onychomycosis** in warm blooded animals such as humans and horses. The method of the present invention is directed to the application of a therapeutic amount of the present composition. In one of the examples provided, the treatment solution is prepared from salicylic acid, NaOH, boric acid and hydrogen peroxide.

ST nail hoof fungus infection treatment soln salicylate peroxide

IT Hoof  
(fungal infection; solns. for treatment of **onychomycosis** in animals)

IT Mycosis  
Nail (anatomical), disease  
(**onychomycosis**; solns. for treatment of **onychomycosis** in animals)

IT Equus caballus  
Human  
Mycosis  
(solns. for treatment of **onychomycosis** in animals)

IT Borates  
Peroxides, biological studies  
Transition metal complexes  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(solns. for treatment of **onychomycosis** in animals)

IT 69-72-7, Salicylic acid, biological studies 69-72-7D, Salicylic acid, derivs. 636-32-8, 1,2,4,5-Tetrahydroxybenzene 7439-89-6D, Iron, complexes 7440-48-4D, Cobalt, complexes 7440-50-8D, Copper, complexes 7440-66-6D, Zinc, complexes 7722-84-1, Hydrogen peroxide., biological studies 7758-98-7, Copper sulfate, biological studies 10043-35-3, Boric acid, biological studies 26062-79-3, Polydadmac  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(solns. for treatment of **onychomycosis** in animals)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Benignus; US 2457025 A 1948 HCAPLUS
- (2) Bernstein; US 2809971 A 1957 HCAPLUS
- (3) Gans; US 5648389 A 1997 HCAPLUS
- (4) Grier; US 3297525 A 1967 HCAPLUS

## 7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> b wpix

FILE 'WPIX' ENTERED AT 10:16:16 ON 21 JUL 2005  
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 20 JUL 2005 <20050720/UP>  
MOST RECENT DERWENT UPDATE: 200546 <200546/DW>  
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE  
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
GUIDES, PLEASE VISIT:  
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT  
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX  
FIRST VIEW - FILE WPIFV.  
FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.  
PLEASE CHECK:  
<http://thomsonderwent.com/support/dwpioref/reftools/classification/code-revision/>  
FOR DETAILS. <<<  
'BIX BI,ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> d all 110 tot

L10 ANSWER 1 OF 2 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-439503 [41] WPIX

CR 2004-106341 [11]

DNC C2004-164549

TI Composition, useful to treat e.g. **onychomycosis**, comprises  
aryloxy derivative, copper composition, peroxide, polyhydroxy aromatic  
compound, transition metal coordination composition and hydrophyllic  
carrier.

DC A96 B05 C03

IN TARBET, B J

PA (TARB-I) TARBET B J

CYC 1

PI US 2004096519 A1 20040520 (200441)\* 5 A61K033-40 <--

ADT US 2004096519 A1 Provisional US 1999-128604P 19990408, Div ex US  
2000-545486 20000410, US 2003-706708 20031111

FDT US 2004096519 A1 Div ex US ~~6680073~~

PRAI US 1999-128604P 19990408; US 2000-545486  
20000410; US 2003-706708 20031111

IC ICM A61K033-40

ICS A61K033-34

AB US2004096519 A UPAB: 20040629

NOVELTY - Composition (C) for treatment of an animal afflicted with  
**onychomycosis** comprises an aryloxy derivative (I), a copper  
composition, a peroxide, a polyhydroxy aromatic compound and a transition  
metal coordination composition all admixed in a hydrophyllic carrier  
composition.

DETAILED DESCRIPTION - Composition (C) for treatment of an animal  
afflicted with **onychomycosis** comprises an aryloxy derivative of  
formula (I), a copper composition, a peroxide, a polyhydroxy aromatic

compound and a transition metal coordination composition all admixed in a hydrophyllic carrier composition.

R1 = H, alkyl, hetero, heteroalkyl, aryl or heteroaryl;  
 R3 = OH, alkyl, hetero, heteroalkyl, aryl or heteroaryl;  
 R2 = hetero; and  
 r7 = H, alkyl, hetero, heteroalkyl, aryl or heteroaryl.

An INDEPENDENT CLAIM is also included for preventing white line disease by applying (C) and a barrier composition (b) to the site of treatment.

ACTIVITY - Fungicide.

MECHANISM OF ACTION - None given.

USE - (C) is useful to treat **onychomycosis** and to treat/prevent whiteline disease (claimed). No details of tests for treating **onychomycosis** are given.

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: A12-V; B05-A03A; B05-C08; B07-H; B10-C01; B10-C03; B10-E02; B10-F02; B10-H01; B14-A04; C05-A03A; C05-C08; C07-H; C10-C01; C10-C03; C10-E02; C10-F02; C10-H01; C14-A04

L10 ANSWER 2 OF 2 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-106341 [11] WPIX

CR 2004-439503 [41]

DNC C2004-043070

TI Fungal infection treatment composition for treating, e.g. **onychomycosis** in animals, includes salicylate compound, copper composition, peroxide, polyhydric aromatic compound, and transition metal coordination complex.

DC C01

IN TARBET, B J

PA (TARB-I) TARBET B J

CYC 1

PI US 6680073 B1 20040120 (200411)\* 4 A01N059-20 <--

ADT US 6680073 B1 Provisional US 1999-128604P 19990408, US 2000-545486 20000410

PRAI US 1999-128604P 19990408; US 2000-545486 20000410

IC ICM A01N059-20

AB US 6680073 B UPAB: 20040629

NOVELTY - A fungal infection treatment composition comprises a salicylate compound (I), a copper composition, a peroxide, polyhydric aromatic compound, and a transition metal coordination complex.

DETAILED DESCRIPTION - A fungal infection treatment composition comprises a compound of formula (I), a copper composition, peroxide, polyhydric aromatic compound, or a transition metal coordination complex, all dissolved in water. It contains greater than 100 mg copper composition.

R2 = hetero (O, S or N).

An INDEPENDENT CLAIM is also included for a pharmaceutical composition for the topical treatment of **onychomycosis** comprising the composition and a carrier.

ACTIVITY - Fungicide.

MECHANISM OF ACTION - None given.

USE - For treatment of fungal infections, e.g. **onychomycosis**, sporotichosis, hoof rot, jungle rot, pseudallecheria boydii, scopolariopsis, or athletes foot in warm blooded animals, e.g. human and horses.

ADVANTAGE - The invention solves the problem of treating a human afflicted with **onychomycosis** without surgery, and has unique properties relative to migration into the infected site.

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: C05-A03; C05-C08; C10-A04; C10-C01; C10-C02; C10-D03; C10-E04; C14-A04

=> b home

FILE 'HOME' ENTERED AT 10:16:22 ON 21 JUL 2005

=>

L23 272 SEA ABB=ON PLU=ON MYCOSIS+NT/CT (L) ?ONYCH?  
 E PEROXIDES/CT  
 E E3+ALL  
 L24 QUE ABB=ON PLU=ON PEROXIDES+OLD,NT/CT  
 E PEROXIDES, BIO/CT  
 L25 6655 SEA ABB=ON PLU=ON "PEROXIDES, BIOLOGICAL STUDIES"/CT  
 L26 2300 SEA ABB=ON PLU=ON ?ONYCH?  
 L27 29 SEA ABB=ON PLU=ON L15 AND (L22 OR L23 OR L26)  
 L28 1 SEA ABB=ON PLU=ON L27 AND L4  
 L29 28 SEA ABB=ON PLU=ON L27 NOT L28  
 L30 3 SEA ABB=ON PLU=ON L29 AND (L16 OR COPPER OR CUPR? OR CU)  
 L31 0 SEA ABB=ON PLU=ON L30 AND (L17 OR L18)  
 L32 0 SEA ABB=ON PLU=ON L30 AND (L19 OR L20 OR L21)  
 L33 0 SEA ABB=ON PLU=ON L30 AND (L24 OR L25)  
 L34 1 SEA ABB=ON PLU=ON L28 AND (L16 OR COPPER OR CUPR? OR CU OR  
 L17 OR L18 OR L24 OR L25)  
 L35 3669 SEA ABB=ON PLU=ON L15 AND (L16 OR COPPER OR CUPR? OR CU OR  
 L17 OR L18 OR L24 OR L25)  
 L36 6 SEA ABB=ON PLU=ON L35 AND (L22 OR L23 OR L26)  
 L37 6 SEA ABB=ON PLU=ON L30 OR L36  
 L38 1 SEA ABB=ON PLU=ON L37 AND L4  
 L39 5 SEA ABB=ON PLU=ON L37 NOT L38  
 L40 1 SEA ABB=ON PLU=ON L38 OR L28 OR L34  
  
 FILE 'USPATFULL, USPAT2' ENTERED AT 11:08:23 ON 21 JUL 2005  
 L41 7416 SEA ABB=ON PLU=ON L15  
 L42 16 SEA ABB=ON PLU=ON L41 AND ONYCH?/TI,IT,AB,CLM  
 E TARBET B/AU  
 L43 33 SEA ABB=ON PLU=ON ("TARBET B"/AU OR "TARBET BRYON J"/AU OR  
 "TARBET BYRON J"/AU)  
 L44 2 SEA ABB=ON PLU=ON L42 AND L43  
 L45 14 SEA ABB=ON PLU=ON L42 NOT L44  
 L46 0 SEA ABB=ON PLU=ON L41 AND (ANTIONYCH? OR ANTI? (1A) ONYCH?)/T  
 I,IT,AB,CLM  
 E COPPER/CT  
 E E4+ALL  
 L47 3 SEA ABB=ON PLU=ON L45 AND (COPPER OR CU OR CUPR? OR TRANSITIO  
 N (1A) METAL? (1A) COMPEX? OR PEROX? OR (POLYHYDROX? OR POLY  
 (1A) (HYDROX? OR OL) OR POLYOL) (2A) AROMAT?)/TI,IT,AB,CLM  
  
 FILE 'HCAPLUS' ENTERED AT 11:14:13 ON 21 JUL 2005  
 L48 185 SEA ABB=ON PLU=ON L15 AND (POLYOL OR POLY(1A)OL)  
 L49 0 SEA ABB=ON PLU=ON L48 AND (L22 OR L23 OR L26)

=> b reg

FILE 'REGISTRY' ENTERED AT 11:17:01 ON 21 JUL 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JUL 2005 HIGHEST RN 856285-74-0  
 DICTIONARY FILE UPDATES: 20 JUL 2005 HIGHEST RN 856285-74-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*

Search done by Noble Jarrell


\* The CA roles and document type information have been removed from \*  
 \* the IDE default display format and the ED field has been added, \*  
 \* effective March 20, 2005. A new display format, IDERL, is now \*  
 \* available and contains the CA role and document type information. \*  
 \* \*  
 \*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d que sta 114  
 '1L4' IS NOT VALID HERE  
 For an explanation, enter "HELP DISPLAY QUERY".

=> d que sta 114  
 L12 STR.



VAR G1=O/S  
 VAR G2=OH/CY/AK  
 NODE ATTRIBUTES:  
 CONNECT IS M1 RC AT 7  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE  
 L14 8205 SEA FILE=REGISTRY CSS FUL L12

100.0% PROCESSED 520380 ITERATIONS 8205 ANSWERS  
 SEARCH TIME: 00.00.06

=> b hcap  
 FILE 'HCAPLUS' ENTERED AT 11:17:22 ON 21 JUL 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

=> d his full:

(FILE 'HOME' ENTERED AT 10:11:44 ON 21 JUL 2005)

FILE 'HCAPLUS' ENTERED AT 10:12:00 ON 21 JUL 2005

L1 1 SEA ABB=ON PLU=ON (US2004096519 OR US6680073)/PN OR US99-1286  
04#/AP,PRN  
E TARBET B/AU  
L2 59 SEA ABB=ON PLU=ON ("TARBET B J"/AU OR "TARBET BRIAN J"/AU OR  
"TARBET BRYON J"/AU)  
L3 1 SEA ABB=ON PLU=ON L2 AND ONYCHO?  
L4 1 SEA ABB=ON PLU=ON L1 OR L3

FILE 'REGISTRY' ENTERED AT 10:14:30 ON 21 JUL 2005

FILE 'HCAPLUS' ENTERED AT 10:14:32 ON 21 JUL 2005

L5 TRA L4 1- RN : 10 TERMS

FILE 'REGISTRY' ENTERED AT 10:14:32 ON 21 JUL 2005

L6 10 SEA ABB=ON PLU=ON L5

FILE 'WPIX' ENTERED AT 10:14:35 ON 21 JUL 2005

L7 2 SEA ABB=ON PLU=ON (US2004096519 OR US6680073)/PN OR US99-1286  
04#/AP,PRN  
E TARBET B/AU  
L8 29 SEA ABB=ON PLU=ON ("TARBET B"/AU OR "TARBET B G"/AU OR  
"TARBET B J"/AU)  
L9 2 SEA ABB=ON PLU=ON L8 AND ONYCH?/BIX,BI,ABEX  
L10 2 SEA ABB=ON PLU=ON L7 OR L9

FILE 'REGISTRY' ENTERED AT 10:39:47 ON 21 JUL 2005

L11 STR  
L12 STR L11  
L13 31 SEA CSS SAM L12  
L14 8205 SEA CSS FUL L12

FILE 'HCAPLUS' ENTERED AT 10:45:52 ON 21 JUL 2005

L15 58489 SEA ABB=ON PLU=ON L14  
E COPPER/CT  
E E3+ALL  
E COPPER CONT/CT  
E COPPER COM/CT  
E E36+ALL  
E COMPOUNDS/CT  
E E3+ALL  
E CHEMISTRY/CT  
E E3+ALL  
L16 QUE ABB=ON PLU=ON CHEMISTRY+NT/CT (L) (COPPER OR CUPR? OR CU)  
E PEROXIDES/CT  
E E3+ALL  
E AROMATIC/CT  
L17 12 SEA ABB=ON PLU=ON (AROMATIC (1A) COMPOUND#)/CW (L) (POLYHYDROX?  
OR POLY(1A)HYDROX?)  
L18 20 SEA ABB=ON PLU=ON AROMATIC/CW (L) (POLYHYDROX? OR POLY(1A)HYDR  
OX?)  
E TRANSITION METAL/CT  
E TRANSITION METAL COMPLEX/CT  
E E4+OLD,NT1  
L19 QUE ABB=ON PLU=ON (TRANSITION (1A) METAL? (1A) COMPLEX?)/CW  
L20 25942 SEA ABB=ON PLU=ON TRANSITION METAL COMPLEXES+OLD/CT  
L21 QUE ABB=ON PLU=ON TRANSITION(1A) METAL? (1A) COMPLEX?  
E NAIL (ANATOMICAL)/CT  
E E3+ALL  
L22 302 SEA ABB=ON PLU=ON "NAIL (ANATOMICAL)"+OLD/CT (L) ?ONYCH?  
E MYCOSIS/CT  
E E3+ALL

Search done by Noble Jarrell



Nail (anatomical), disease  
 (onychomycosis; solns. for treatment of onychomycosis  
 in animals)

IT Equus caballus  
 Human  
 Mycosis  
 (solns. for treatment of onychomycosis in animals)


IT Borates  
 Peroxides, biological studies  
 Transition metal complexes  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (solns. for treatment of onychomycosis in animals)

IT 69-72-7, Salicylic acid, biological studies 69-72-7D,  
 Salicylic acid, derivs. 636-32-8, 1,2,4,5-Tetrahydroxybenzene  
 7439-89-6D, Iron, complexes 7440-48-4D, Cobalt, complexes 7440-50-8D,  
 Copper, complexes 7440-66-6D, Zinc, complexes 7722-84-1  
 , Hydrogen peroxide., biological studies 7758-98-7, Copper  
 sulfate, biological studies 10043-35-3, Boric acid, biological studies  
 26062-79-3, Polyadamac  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (solns. for treatment of onychomycosis in animals)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE  
 (1) Benignus; US 2457025 A 1948 HCAPLUS  
 (2) Bernstein; US 2809971 A 1957 HCAPLUS  
 (3) Gans; US 5648389 A 1997 HCAPLUS  
 (4) Grier; US 3297525 A 1967 HCAPLUS  
 (5) Howard; US 6099854 A 2000 HCAPLUS  
 (6) Leebrick; US 3287210 A 1966 HCAPLUS  
 (7) McFadden; US 3228830 A 1966 HCAPLUS  
 (8) Patterson; US 2066363 A 1937 HCAPLUS  
 (9) Yeaser; US 3288674 A 1966 HCAPLUS

IT 69-72-7, Salicylic acid, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (solns. for treatment of onychomycosis in animals)

RN 69-72-7 HCAPLUS  
 CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



=> d all hitstr 139 tot

L39 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:569681 HCAPLUS  
 DN 141:117191  
 ED Entered STN: 16 Jul 2004  
 TI Seborrheic keratosis treatment using hydrogen peroxide  
 IN Ancira, Margaret; Miller, Mickey  
 PA USA  
 SO U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 72,829.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K033-40  
 INCL 424616000; 514474000; 514561000; 514276000; 514250000; 514356000  
 CC 1-12 (Pharmacology)  
 Section cross-reference(s): 63  
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

Search done by Noble Jarrell

PI	US 2004137077	A1	20040715	US 2003-684136	20031009
	US 2003008018	A1	20030109	US 2002-72829	20020208
PRAI	US 2001-267978P	P	20010209		
	US 2002-72829	A2	20020208		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004137077	ICM	A61K033-40
	INCL	424616000; 514474000; 514561000; 514276000; 514250000; 514356000
US 2004137077	NCL	424/616.000; 514/474.000; 514/561.000; 514/276.000; 514/250.000; 514/356.000
	ECLA	A61K008/33; A61K033/40; A61K033/40+M
US 2003008018	NCL	424/616.000; 514/474.000; 514/251.000; 514/356.000; 514/276.000
	ECLA	A61K008/33; A61K033/40; A61K033/40+M
AB	The subject of the present invention is seborrheic keratosis removal and prevention utilizing safe dependable effective biocompatible treatments with no scarring, bleeding, burning, freezing, shocking, and hypopigmentation or hyperpigmentation. Seborrheic keratoses are removed by: (a) obtaining a composition comprising hydrogen peroxide in a concentration of at least about 23 %; and (b) applying the composition to a seborrheic keratosis on a seborrheic keratoses afflicted person or domesticated animal. Patients were treated with applications of 35 % hydrogen peroxide. Compns. are presented.	
ST	seborrheic keratosis removal hydrogen peroxide	
IT	Keratosis (actinic, treatment of; seborrheic keratosis treatment using hydrogen peroxide)	
IT	Infection Reproductive tract, neoplasm (acuminate wart, treatment of; seborrheic keratosis treatment using hydrogen peroxide)	
IT	Wart (acuminate, genital, treatment of; seborrheic keratosis treatment using hydrogen peroxide)	
IT	Skin, disease (aging, rhytides, treatment of; seborrheic keratosis treatment using hydrogen peroxide)	
IT	Quaternary ammonium compounds, biological studies RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkylbenzyl dimethyl, chlorides, as surfactant, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)	
IT	Brushes Injectors Pipets Spray atomizers Spraying apparatus (application using; seborrheic keratosis treatment using hydrogen peroxide)	
IT	Rumex crispus (as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)	
IT	Glycosides RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)	
IT	Lecithins RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (as surfactant, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)	
IT	Cananga odorata	

Chenopodium  
 Eucalyptus  
 Pimpinella anisum  
   (as terpene, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Skin, neoplasm  
   (basal cell carcinoma, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Carcinoma  
   (basal cell, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Fats and Glyceridic oils, biological studies  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
   (borage seed, as  $\gamma$ -linolenic precursor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Skin, disease  
   (clear cell acanthoma, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Melanins  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
   (composition containing inhibitor of; seborrheic keratosis treatment using hydrogen peroxide)

IT Aloe barbadensis  
 Surfactants  
 Witch hazel  
   (composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Alcohols, biological studies  
 Amides, biological studies  
 Estrogens  
 Fatty acids, biological studies  
 Hormones, animal, biological studies  
 Ketones, biological studies  
 Polyoxyalkylenes, biological studies  
 Sulfoxides  
 Terpenes, biological studies  
 Thymus hormones  
 Thyroid hormones  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
   (composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Protein hydrolyzates  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
   (conchiolin hydrolyzates, as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Albuminoids  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
   (conchiolins, hydrolyzates, as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Skin, disease  
   (corn, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Fats and Glyceridic oils, biological studies  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
   (currant, Ribes nigrum seed, as  $\gamma$ -linolenic precursor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Carcinoma  
   (cutaneous squamous cell, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Papilloma

- (cutaneous, treatment of; seborrheic keratosis treatment using hydrogen peroxide)
- IT Medical goods
  - (droppers, application using; seborrheic keratosis treatment using hydrogen peroxide)
- IT Fatty acids, biological studies
  - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (esters, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)
- IT Fats and Glyceridic oils, biological studies
  - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (evening primrose, as  $\gamma$ -linolenic precursor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)
- IT Arctostaphylos uva-ursi
  - Haematoxylon campechianum
  - Vaccinium myrtillus
  - (extract, as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)
- IT Skin, disease
  - (fibroepithelial polyps, treatment of; seborrheic keratosis treatment using hydrogen peroxide)
- IT Infection
  - Skin, disease
  - (herpes, treatment of; seborrheic keratosis treatment using hydrogen peroxide)
- IT Skin, disease
  - (hyperpigmentation, treatment of; seborrheic keratosis treatment using hydrogen peroxide)
- IT Keratosis
  - (inverted follicular keratosis, treatment of; seborrheic keratosis treatment using hydrogen peroxide)
- IT Natural products, pharmaceutical
  - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (licorice, as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)
- IT Mycosis
  - Nail (anatomical), disease
  - (onychomycosis, treatment of; seborrheic keratosis treatment using hydrogen peroxide)
- IT Acids, biological studies
  - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (organic, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)
- IT Skin, neoplasm
  - (papilloma, treatment of; seborrheic keratosis treatment using hydrogen peroxide)
- IT Drug delivery systems
  - (patches, application using; seborrheic keratosis treatment using hydrogen peroxide)
- IT Alcohols, biological studies
  - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (polyhydric, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)
- IT Phenols, biological studies
  - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (polyphenols, nonpolymeric, as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)
- IT Pruritus
  - (prurigo nodularis, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Pueraria  
(root, as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Skin, disease  
(rosacea, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Domestic animal  
Human  
(seborrheic keratosis treatment using hydrogen peroxide)

IT Peroxides, biological studies  
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(seborrheic keratosis treatment using hydrogen peroxide)

IT Amino acids, biological studies  
Vitamins  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(seborrheic keratosis treatment using hydrogen peroxide)

IT Keratosis  
(seborrheic; seborrheic keratosis treatment using hydrogen peroxide)

IT Lithospermum  
(seed extract, as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Skin, neoplasm  
Skin, neoplasm  
(squamous cell carcinoma, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Carcinoma  
(squamous cell, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Foot  
(toe, disease, corn, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Acne  
Melanoma  
Psoriasis  
Wart  
(treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Skin, disease  
(warty dyskeratosis, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT 53-86-1D, Indomethacin, derivs. 60-33-3, Linoleic acid, biological studies 69-72-7D, Salicylic acid, alkyl derivs. 79-09-4, Propionic acid, biological studies 83-86-3, Phytic acid 98-92-0, Niacinamide 108-95-2, Phenol, biological studies 123-31-9, Hydroquinone, biological studies 123-31-9D, Hydroquinone, glycosides 123-99-9, Azelaic acid, biological studies 137-66-6, Ascorbyl palmitate 288-47-1D, Thiazole, compds. 331-39-5, Caffeic acid 461-72-3, Hydantoin 476-66-4, Ellagic acid 491-38-3D, Chromone, derivs. 497-76-7, Arbutin 501-30-4, Kojic acid 501-30-4D, Kojic acid, dimer 501-30-4D, Kojic acid, glycosides 621-82-9, Cinnamic acid, biological studies 636-58-8 1182-34-9, Dicafeoylquinic acid 1197-18-8, Tranexamic acid 1405-86-3, Glycyrrhizic acid 7704-34-9, Sulfur, biological studies 9012-76-4, Chitosan 9054-89-1, Superoxide dismutase 9083-38-9, Melanostatin 12001-79-5, Vitamin K 25138-66-3, S-Lactoyl glutathione 27025-41-8, Oxidized glutathione 37299-36-8, Lavanol 56328-22-4 86632-03-3 108910-78-7, Magnesium ascorbyl phosphate  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT 57-09-0, Cetyltrimethylammonium bromide 112-00-5, Dodecyltrimethylammonium chloride 112-02-7, Hexadecyltrimethylammonium chloride 112-03-8, Octadecyltrimethylammonium chloride 123-03-5, Cetylpyridinium chloride 145-42-6, Sodium taurocholate 151-21-3, Sodium lauryl sulfate, biological studies 302-95-4, Sodium desoxycholate

361-09-1, Sodium cholate 629-25-4, Sodium laurate 1119-97-7, Tetradecyltrimethylammonium bromide 1338-39-2, Span 20 1338-41-6, Span 60 1338-43-8, Span 80 2836-32-0, Sodium glycolate 9002-92-0, Brij 30 9004-98-2, Brij 93 9004-99-3, Myrj 45 26266-57-9, Span 40 77466-09-2, Miglyol 840 106392-12-5, Poloxamer 231  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (as surfactant, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT 80-56-8,  $\alpha$ -Pinene 89-80-5, Menthone 89-81-6, Piperitone 89-82-7, Pulegone 98-55-5,  $\alpha$ -Terpineol 99-48-9, Carveol 99-49-0, Carvone 285-67-6, Cyclopentene oxide 286-20-4, Cyclohexene oxide 470-82-6, 1,8-Cineole 554-60-9,  $\beta$ -Carene 562-74-3, Terpinen-4-ol 1195-92-2, Limonene oxide 1686-14-2,  $\alpha$ -Pinene oxide 5989-27-5, D-Limonene  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (as terpene, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT 9002-72-6, Growth hormone  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (composition further containing human; seborrheic keratosis treatment using hydrogen peroxide)

IT 506-26-3, Gamma linolenic acid  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (composition further containing precursor for; seborrheic keratosis treatment using hydrogen peroxide)

IT 50-21-5, Lactic acid, biological studies 53-43-0, Dehydroepiandrosterone 56-81-5, Glycerol, biological studies 57-11-4, Stearic acid, biological studies 57-13-6, Urea, biological studies 57-55-6, Propylene glycol, biological studies 57-83-0, Progesterone, biological studies 58-22-0, Testosterone 64-17-5, Ethanol, biological studies 67-68-5, Dimethyl sulfoxide, biological studies 67-71-0, Methylsulfonylmethane 68-12-2, Dimethylformamide, biological studies 69-72-7, Salicylic acid, biological studies 71-23-8, Propanol, biological studies 71-36-3, Butanol, biological studies 71-41-0, Pentanol, biological studies 73-31-4, Melatonin 77-92-9, Citric acid, biological studies 78-92-2, 2-Butanol 79-14-1, Glycolic acid, biological studies 79-20-9, Methyl acetate 79-33-4, L-Lactic acid, biological studies 80-69-3, Tartronic acid 87-69-4, Tartaric acid, biological studies 87-73-0, Saccharic acid 90-64-2, Mandelic acid 100-51-6, Benzyl alcohol, biological studies 102-71-6, Triethanolamine, biological studies 107-21-1, Ethylene glycol, biological studies 109-52-4, Valeric acid, biological studies 110-15-6, Succinic acid, biological studies 110-27-0, Isopropyl myristate 110-40-7, Diethyl sebacate 111-14-8, Heptanoic acid 111-27-3, Hexanol, biological studies 111-42-2, Diethanolamine, biological studies 111-46-6, Diethylene glycol, biological studies 111-62-6, Ethyl oleate 111-65-9, N-Octane, biological studies 111-84-2, N-Nonane 111-87-5, Octanol, biological studies 112-05-0, Pelargonic acid 112-27-6, Triethylene glycol 112-30-1, Decanol 112-40-3, N-Dodecane 112-80-1, Oleic acid, biological studies 123-86-4, Butyl acetate 124-07-2, Caprylic acid, biological studies 124-18-5, N-Decane 127-17-3, Pyruvic acid, biological studies 127-19-5, Dimethylacetamide 134-62-3, Diethyltoluamide 141-78-6, Ethyl acetate, biological studies 142-62-1, Caproic acid, biological studies 142-82-5, N-Heptane, biological studies 142-91-6, Isopropyl palmitate 143-07-7, Lauric acid, biological studies 143-08-8, Nonanol 145-13-1, Pregnenolone 156-06-9,  $\beta$ -Phenylpyruvic acid 320-77-4, Isocitric acid 334-48-5, Capric acid 433-48-7,  $\beta$ -Fluoropyruvic acid 473-81-4, Glyceric acid 497-76-7D, Arbutin, isomers 515-30-0, Atrolactic acid 526-95-4, Gluconic acid 526-99-8, Mucic acid 544-63-8, Myristic acid, biological studies 544-76-3, N-Hexadecane 554-12-1, Methyl propionate 594-61-6, 2-Hydroxyisobutyric acid 600-15-7,  $\alpha$ -Hydroxybutyric acid 624-24-8, Methyl valerate

629-50-5, N-Tridecane 629-59-4, N-Tetradecane 685-73-4, Galacturonic acid 828-01-3,  $\beta$ -Phenyllactic acid 1118-92-9 1120-21-4, N-Undecane 3079-28-5, Decyl methyl sulfoxide 3402-98-0, Iduronic acid 3416-24-8, Glucosamine 5699-58-1, Acetylpyruvic acid 6032-29-7, 2-Pentanol 6556-12-3, Glucuronic acid 6703-05-5, Lyxaric acid 6814-36-4, Mannuronic acid 6915-15-7, Malic acid 10158-64-2, Xylaric acid 14433-76-2 15769-56-9, Guluronic acid 18494-60-5 23351-51-1, Glucoheptonic acid 24871-35-0, Altronic acid 25265-71-8, Dipropylene glycol 25322-68-3, Polyethylene glycol 28223-51-0, Alluronic acid 28223-52-1, Taluronic acid 30923-19-4, Lyxuronic acid 30923-20-7, Riburonic acid 30923-21-8, Xyluronic acid 30923-39-8, Arabinuronic acid 36413-60-2, Quinic acid 66664-08-2, Pentahydroxyhexanoic acid 83826-43-1, Octyldodecyl myristate 84710-55-4, Threuric acid 84710-56-5, Erythreuric acid 474655-00-0 722493-20-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT 94-36-0, Benzoyl peroxide, biological studies 7722-84-1,

Hydrogen peroxide, biological studies

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);

THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(seborrheic keratosis treatment using hydrogen peroxide)

IT 50-81-7, Ascorbic acid, biological studies 52-90-4, L-Cysteine,

biological studies 56-40-6, Glycine, biological studies 56-41-7,

L-Alanine, biological studies 56-45-1, L-Serine, biological studies

56-85-9, L-Glutamine, biological studies 56-87-1, L-Lysine, biological

studies 56-89-3, L-Cystine, biological studies 59-43-8, Thiamin,

biological studies 59-67-6, Niacin, biological studies 60-18-4,

L-Tyrosine, biological studies 61-90-5, L-Leucine, biological studies

63-68-3, L-Methionine, biological studies 63-91-2, L-Phenylalanine,

biological studies 70-26-8, L-Ornithine 70-47-3, L-Asparagine,

biological studies 71-00-1, L-Histidine, biological studies 72-18-4,

L-Valine, biological studies 72-19-5, L-Threonine, biological studies

73-22-3, L-Tryptophan, biological studies 73-32-5, L-Isoleucine,

biological studies 74-79-3, L-Arginine, biological studies 83-88-5,

Riboflavin, biological studies 147-85-3, L-Proline, biological studies

305-84-0, Carnosine 541-15-1, L-Carnitine 1190-94-9, 5-Hydroxylysine

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(seborrheic keratosis treatment using hydrogen peroxide)

IT 79-17-4, Aminoguanidine 7732-18-5, Water, biological studies

9067-32-7, Sodium hyaluronate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(seborrheic keratosis treatment using hydrogen peroxide)

IT 69-72-7D, Salicylic acid, alkyl derivs.


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

RN 69-72-7 HCAPLUS

CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



IT 69-72-7, Salicylic acid, biological studies


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)


(composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

RN 69-72-7 HCAPLUS

CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



IT 94-36-0, Benzoyl peroxide, biological studies 7722-84-1,  
Hydrogen peroxide, biological studies  
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(seborrheic keratosis treatment using hydrogen peroxide)  
RN 94-36-0 HCAPLUS  
CN Peroxide, dibenzoyl (9CI) (CA INDEX NAME)



RN 7722-84-1 HCAPLUS  
CN Hydrogen peroxide (H2O2) (9CI) (CA INDEX NAME)

HO-OH

L39 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN  
AN 2002:391479 HCAPLUS  
DN 136:390755  
ED Entered STN: 24 May 2002  
TI Antifungal nail composition containing a copper salt  
IN Zeiler, Kenneth T.  
PA USA  
SO PCT Int. Appl., 23 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
IC ICM A61K007-04  
ICS A61K033-34  
CC 62-4 (Essential Oils and Cosmetics)  
Section cross-reference(s): 1, 63  
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002039963	A1	20020523	WO 2001-US29438	20010919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2431651 AA 20020523 CA 2001-2431651 20010919 AU 2001092866 A5 20020527 AU 2001-92866 20010919 EP 1341500 A1 20030910 EP 2001-973268 20010919 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR JP 2004513905 T2 20040513 JP 2002-542338 20010919 US 2004001791 A1 20040101 US 2003-440468 20030516				



PRAI US 2000-249381P P 20001116  
 US 2001-286781P P 20010426  
 WO 2001-US29438 W 20010919  
 US 2002-421257P P 20021025

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002039963	ICM	A61K007-04
	ICS	A61K033-34
WO 2002039963	ECLA	A61K007/04D; A61K031/28; A61K033/34
JP 2004513905	FTERM	4C076/AA11; 4C076/AA94; 4C076/BB31; 4C076/CC20; 4C076/CC31; 4C076/FF31; 4C083/AB101; 4C083/AB211; 4C083/AB311; 4C083/AB351; 4C083/AB352; 4C083/AC271; 4C083/AC301; 4C083/AC311; 4C083/AC471; 4C083/AC931; 4C083/CC28; 4C083/DD23; 4C083/DD27; 4C083/EE50; 4C086/AA01; 4C086/AA02; 4C086/BC28; 4C086/DA17; 4C086/HA01; 4C086/HA21; 4C086/HA24; 4C086/HA26; 4C086/HA28; 4C086/MA01; 4C086/MA17; 4C086/MA63; 4C086/ZA90; 4C086/ZB35; 4C206/AA01; 4C206/AA02; 4C206/DA07; 4C206/DA13; 4C206/DA19; 4C206/JB01; 4C206/MA01; 4C206/MA37; 4C206/MA83; 4C206/NA12; 4C206/ZA90; 4C206/ZB35
US 2004001791	NCL	424/061.000; 424/637.000
	ECLA	A61K031/30; A61K033/34

AB A method for treating onychomycosis in humans comprises contacting a fungi-infected nail with a composition comprising an effective amount of a copper salt. Most preferably, the fungi-infected nail is treated with 10% (weight/weight) aqueous copper(II) sulfate. The nail composition released copper salt over time in a controlled-release fashion. Treating human nails with the copper salt composition can be used to detect fungal infection before routine phys. symptoms are presented due to staining of fungi-infected human nail tissue by a copper salt. Fungal infection is also prevented by pre-treatment of nails with the copper salt composition

ST copper salt controlled release antifungal nail cosmetic

IT Fungicides

Human

(antifungal nail composition containing copper salts)

IT Acrylic polymers, biological studies

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)

(antifungal nail composition containing copper salts)

IT Nail (anatomical)

(artificial; antifungal nail composition containing copper salts)

IT Drug delivery systems

(controlled-release, topical; antifungal nail composition containing copper salts)

IT Naphthenic acids, biological studies

RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(copper salts; antifungal nail composition containing copper salts)

IT Hand

Nail (anatomical)

(fingernail; antifungal nail composition containing copper salts)

IT Cosmetics

(gels; antifungal nail composition containing copper salts)

IT Cosmetics

(nail lacquers; antifungal nail composition containing copper salts)

IT Mycosis

Nail (anatomical), disease

(onychomycosis; antifungal nail composition containing copper salts)

IT Foot

Nail (anatomical)

(toenail; antifungal nail composition containing copper salts)

IT 527-09-3, Copper gluconate 1344-70-3, Copper oxide

4180-12-5, Copper acetate 7440-50-8D, Copper, ammonium complexes and salts 7492-68-4, Copper carbonate 7758-98-7, Copper sulfate, biological studies 16039-52-4, Copper lactate 16048-96-7, Copper(II) salicylate 18970-62-2 27004-40-6, Copper tartrate 40974-00-3, Copper perchlorate 70027-50-8, Copper selenate

RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antifungal nail composition containing copper salts)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Aquanautics Corp; WO 9311735 A 1993 HCAPLUS
- (2) Aron, R; US 3257280 A 1966 HCAPLUS
- (3) Butler, H; MEDICAL JOURNAL OF AUSTRALIA 1970, V2, P309 MEDLINE
- (4) Corliss, L; US 4822595 A 1989 HCAPLUS
- (5) Fitolon Co Ltd; RU 2063744 C 1996 HCAPLUS
- (6) Intr Prod Cosmetice Miraj; RO 88114 A 1985
- (7) Passarelli, M; US 4933175 A 1990
- (8) Scivoletto, R; WO 9852927 A 1998 HCAPLUS


IT 16048-96-7, Copper(II) salicylate

RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antifungal nail composition containing copper salts)

RN 16048-96-7 HCAPLUS

CN Copper, bis[2-(hydroxy-κO)benzoato-κO]- (9CI) (CA INDEX NAME)



L39 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:353986 HCAPLUS

DN 136:359653

ED Entered STN: 12 May 2002

TI Pharmaceutical compositions for managing skin conditions

IN Murad, Howard

PA USA

SO U.S. Pat. Appl. Publ., 19 pp., Cont.-in-part of U.S. 878,231.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K033-40

ICS A61K035-78

INCL 424616000

CC 63-6 (Pharmaceuticals)

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002054918	A1	20020509	US 2001-953431	20010917
	US 6673374	B2	20040106		
	US 2002041901	A1	20020411	US 2001-878231	20010612
	US 6383523	B1	20020507		
	US 2003007939	A1	20030109	US 2002-77928	20020220

Search done by Noble Jarrell

	US 2004091548	A1	20040513	US 2003-702453	20031107
PRAI	US 2001-878231	A2	20010612		
	US 1998-94775P	P	19980731		
	US 1999-330127	A2	19990611		
	US 2000-549202	A1	20000413		
	US 2001-953431	A2	20010917		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2002054918	ICM	A61K033-40
	ICS	A61K035-78
	INCL	424616000
US 2002054918	NCL	424/616.000; 514/248.000; 514/616.000; 514/714.000; 514/739.000
	ECLA	A61K008/22; A61K033/40+M; A61K045/06; A61Q019/00
US 2002041901	NCL	424/616.000; 514/396.000; 514/557.000; 514/568.000; 514/574.000; 514/739.000
	ECLA	A61K008/22; A61K008/365; A61K008/60A; A61K008/97; A61K033/40+M; A61K045/06; A61Q019/00; C11D003/00B13; C11D003/20E5
US 2003007939	NCL	424/061.000; 424/070.100; 424/616.000
	ECLA	A61K008/22; C11D003/20E5; A61K008/365; A61K008/60A; A61K008/97; A61K033/40+M; A61K045/06; A61Q019/00; C11D003/00B13
US 2004091548	NCL	424/616.000
	ECLA	A61K008/22; A61K008/365; A61K008/60A; A61K008/97; A61K033/40+M; A61K045/06; A61Q019/00; C11D003/00B13; C11D003/20E5

AB This application relates to a pharmaceutical composition and methods for treating inflammatory skin conditions. The comps. include hydrogen peroxide, 1 or more moisturizing agents, and an anti-inflammatory agent. The pharmaceutical comps. may optionally include 1 or more exfoliants. The comps. can be used to treat inflammatory skin conditions such as dermatitis, including, but not limited to seborrheic dermatitis, nummular dermatitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, and stasis dermatitis; psoriasis; folliculitis; rosacea; acne; impetigo; erysipelas; paronychia, erythrasma; and eczema. A skin cleanser formulation contained water 49.2, trisodium EDTA 10, Mackanate EL 17, Monateric CDX-38 11, Crothix 1.5, Kessco PEG-6000 DS 0.7, methylparaben 0.2, salicylic acid 1.6, citric acid 1.5, Irgasan DP-300 0.3, Solibilisant LR1 2, fragrance 0.3, menthol 0.1, butylene glycol 0.1, Snakeroot BG50 0.1, Ajidew-50 0.2, Phospholipid PTC 1, and 35% H2O2 solution 3%.

ST pharmaceutical hydrogen peroxide skin disorder

IT Surfactants

(amphoteric; pharmaceutical comps. for managing skin conditions)

IT Dermatitis

(atopic; pharmaceutical comps. for managing skin conditions)

IT Fats and Glyceridic oils, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(borage seed; pharmaceutical comps. for managing skin conditions)

IT Cosmetics

(cleansing; pharmaceutical comps. for managing skin conditions)

IT Skin, disease

(erysipelas; pharmaceutical comps. for managing skin conditions)

IT Skin, disease

(erythrasma; pharmaceutical comps. for managing skin conditions)

IT Fats and Glyceridic oils, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(fish, n-3 fatty acid-high; pharmaceutical comps. for managing skin conditions)

IT Fats and Glyceridic oils, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(fish, n-6 fatty acid-high; pharmaceutical comps. for managing skin conditions)

IT Hair

(folliculitis; pharmaceutical comps. for managing skin conditions)

IT Carboxylic acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hydroxy; pharmaceutical compns. for managing skin conditions)

IT Skin, disease  
 (impetigo; pharmaceutical compns. for managing skin conditions)

IT Drug delivery systems  
 (lotions; pharmaceutical compns. for managing skin conditions)

IT Cosmetics  
 (moisturizers; pharmaceutical compns. for managing skin conditions)

IT Amino acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (of keratin; pharmaceutical compns. for managing skin conditions)

IT Acne  
 Analgesics  
 Anesthetics  
 Anti-inflammatory agents  
 Antibacterial agents  
 Antioxidants  
 Dermatitis  
 Eczema  
 Fungicides  
 Paronychia  
 Preservatives  
 Psoriasis  
 Seborrhea  
 Skin preparations (pharmaceutical)  
 Stabilizing agents  
 (pharmaceutical compns. for managing skin conditions)

IT Ceramides  
 Keratins  
 Linseed oil  
 Tannins  
 Tocopherols  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical compns. for managing skin conditions)

IT Fats and Glyceridic oils, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (primrose; pharmaceutical compns. for managing skin conditions)

IT Skin, disease  
 (rosacea; pharmaceutical compns. for managing skin conditions)

IT Drug delivery systems  
 (topical; pharmaceutical compns. for managing skin conditions)

IT Proteins  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (wheat; pharmaceutical compns. for managing skin conditions)

IT 7722-84-1, Hydrogen peroxide, biological studies  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (pharmaceutical compns. for managing skin conditions)

IT 50-21-5, Lactic acid, biological studies 50-78-2, Aspirin  
 56-81-5, Glycerin, biological studies 60-33-3, Linoleic acid, biological  
 studies 69-72-7, Salicylic acid, biological studies 77-92-9,  
 Citric acid, biological studies 79-14-1, Glycolic acid, biological  
 studies 81-13-0, Panthenol 9004-61-9, Hyaluronic acid 9006-65-9,  
 Dimethicone 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1,  
 Naproxen 28874-51-3 51744-92-4  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical compns. for managing skin conditions)

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD


RE

(1) af Ekenstam; US 4557935 A 1985 HCAPLUS  
 (2) Anon; GB 1135643 1968 HCAPLUS  
 (3) Anon; GB 2076286 1981 HCAPLUS  
 (4) Anon; CA 1174976 1984 HCAPLUS  
 (5) Anon; EP 0191214 1986 HCAPLUS  
 (6) Anon; GB 2189394 1987 HCAPLUS


(7) Anon; EP 2250539 1991  
 (8) Anon; EP 0425507 1995  
 (9) Bansemir; US 4900721 A 1990 HCAPLUS  
 (10) Barton; US 5695745 A 1997 HCAPLUS  
 (11) Bekele; US 6495150 B2 2002 HCAPLUS  
 (12) Bowing; US 4051058 A 1977 HCAPLUS  
 (13) Bowing; US 4051059 A 1977 HCAPLUS  
 (14) Burke; US 5296215 A 1994 HCAPLUS  
 (15) Burke; US 5693318 A 1997  
 (16) Claey's; US 4203765 A 1980  
 (17) Coats; US 4178372 A 1979 HCAPLUS  
 (18) Cook; US 5008030 A 1991 HCAPLUS  
 (19) De Grandis; Rib. ital. Essenze 1974, V56(7), P371 HCAPLUS  
 (20) Devillez; US 5958984 A 1999 HCAPLUS  
 (21) Dresdner; US 5357636 A 1994  
 (22) Gallina; US 4514384 A 1985 HCAPLUS  
 (23) Ganci; US 4438102 A 1984 HCAPLUS  
 (24) Greene; US 4557898 A 1985 HCAPLUS  
 (25) Hall; US 5547990 A 1996 HCAPLUS  
 (26) Herb; US 6022547 A 2000 HCAPLUS  
 (27) Hopkins; US 4534945 A 1985 HCAPLUS  
 (28) Jarrett; US 5593952 A 1997 HCAPLUS  
 (29) Mills; vol. I 1982, V4, P233  
 (30) Newell; US 3297456 A 1967 HCAPLUS  
 (31) Oliver; US 5869062 A 1999 HCAPLUS  
 (32) Robinson; US 5474768 A 1995 HCAPLUS  
 (33) Rovati; US 5177099 A 1993 HCAPLUS  
 (34) Sawaya; US 5519059 A 1996 HCAPLUS  
 (35) Schmidt; US 5139788 A 1992 HCAPLUS  
 (36) Scholz; US 5951993 A 1999 HCAPLUS  
 (37) Skiar; US 5861432 A 1999 HCAPLUS  
 (38) Smith; US 6491928 B1 2002 HCAPLUS  
 (39) Song; US 5843998 A 1998 HCAPLUS  
 (40) Wile; Current. Med. res. Opin. 1986, V10(2), P82 HCAPLUS  
 (41) Yu; US 5641475 A 1997 HCAPLUS  
 IT 7722-84-1, Hydrogen peroxide, biological studies  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (pharmaceutical compns. for managing skin conditions)  
 RN 7722-84-1 HCAPLUS  
 CN Hydrogen peroxide (H2O2) (9CI) (CA INDEX NAME)

HO-OH

IT 50-78-2, Aspirin 69-72-7, Salicylic acid, biological  
 studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical compns. for managing skin conditions)  
 RN 50-78-2 HCAPLUS  
 CN Benzoic acid, 2-(acetyloxy)- (9CI) (CA INDEX NAME)



RN 69-72-7 HCAPLUS  
 CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



L39 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1999:90501 HCAPLUS  
 DN 130:150435  
 ED Entered STN: 12 Feb 1999  
 TI Phototherapy-based method and composition for treating pathogens  
 IN Lurie, Raz  
 PA Dermatolazer Technologies Ltd., Israel; Friedman, Mark, M.  
 SO PCT Int. Appl., 37 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A01N025-00  
 CC 8-9 (Radiation Biochemistry)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9904628	A1	19990204	WO 1998-US14162	19980713	
	W:			AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:			GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	CA 2298526	AA	19990204	CA 1998-2298526	19980713	
	AU 9884788	A1	19990216	AU 1998-84788	19980713	
	AU 750933	B2	20020801			
	EP 1005267	A1	20000607	EP 1998-935571	19980713	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI		
	JP 2001510773	T2	20010807	JP 2000-503708	19980713	
	US 6090788	A	20000718	US 1999-343199	19990630	
PRAI	US 1997-901426	A	19970728			
	WO 1998-US14162	W	19980713			

## CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 9904628	ICM	A01N025-00
	WO 9904628	ECLA	A61K041/00H6; A61N005/06C8
	US 6090788	NCL	514/023.000; 427/595.000; 427/596.000; 606/002.000; 606/003.000
		ECLA	A61K031/00+A; A61K031/352; A61K031/409
AB	A method for treating an area of skin or nail affected with a pathogen comprises irradiating the area of skin or nail with a light beam having at least one wavelength absorbable by the pathogen.		
ST	phototherapy skin nail pathogen		
IT	Inks (India; phototherapy-based method and composition for treating pathogens)		
IT	Spore (ascospore, stain; phototherapy-based method and composition for treating pathogens)		
IT	Porphyrins RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (benzoporphyrins, derivative, monoacid; phototherapy-based method and composition for treating pathogens)		
IT	Drugs (bioreductive; phototherapy-based method and composition for treating pathogens)		

IT Inks  
(black; phototherapy-based method and composition for treating pathogens)

IT Drugs  
(conjugates with pigments; phototherapy-based method and composition for treating pathogens)

IT Immunoglobulins  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(conjugates, with pigments; phototherapy-based method and composition for treating pathogens)

IT Flours and Meals  
(corn, dextrose; phototherapy-based method and composition for treating pathogens)

IT Potato (*Solanum tuberosum*)  
(dextrose; phototherapy-based method and composition for treating pathogens)

IT Nail (anatomical)  
(disease, onychomycosis; phototherapy-based method and composition for treating pathogens)

IT Hair preparations  
(dyes; phototherapy-based method and composition for treating pathogens)

IT Porphyrins  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hematoporphyrins; phototherapy-based method and composition for treating pathogens)

IT Skin, disease  
(infection; phototherapy-based method and composition for treating pathogens)

IT Corn  
(meal, dextrose; phototherapy-based method and composition for treating pathogens)

IT Nail (anatomical)  
(onychomycosis; phototherapy-based method and composition for treating pathogens)

IT Drug delivery systems  
(oral; phototherapy-based method and composition for treating pathogens)

IT Antimalarials  
Drug delivery systems  
Dyes  
IR laser radiation  
Nail (anatomical)  
Nutrients  
Pathogen  
Photodynamic therapy  
Phototherapy  
Pigments, nonbiological  
Stains, biological  
Trichophyton mentagrophytes  
Trichophyton rubrum  
UV radiation  
(phototherapy-based method and composition for treating pathogens)

IT Carotenes, biological studies  
Chlorophylls, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(phototherapy-based method and composition for treating pathogens)

IT Foot  
Foot  
Nail (anatomical)  
Nail (anatomical)  
(toenail; phototherapy-based method and composition for treating pathogens)

IT Drug delivery systems  
(topical; phototherapy-based method and composition for treating pathogens)

IT 9002-89-5, Polyvinyl alcohol  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(loctophenol cotton blue with; phototherapy-based method and composition for treating pathogens)

IT 50-99-7, Dextrose, biological studies 57-13-6, Urea, biological studies  
61-73-4, Methylene blue 69-72-7, Salicylic acid, biological

studies 76-59-5, Bromthymol blue 83-88-5, Riboflavin, biological studies 85-83-6, Scarlet red 88-89-1, Picric acid 92-84-2D, Phenothiazine, derivs. 106-60-5, 5-Aminolevulinic acid 115-40-2, Bromcresol purple 143-74-8, Phenol red 314-13-6, Evans blue 479-61-8D, derivs. 502-65-8, Lycopene 569-61-9, Pararosaniline chloride 574-93-6, Phthalocyanine 633-03-4, Brilliant green 2030-63-9, Clofazimine 2412-14-8, Thiopyronin 4197-24-4 7439-89-6, Iron, biological studies 7439-89-6D, Iron, salts, biological studies 7439-97-6, Mercury, biological studies 7440-22-4, Silver, biological studies 7440-50-8, Copper, biological studies 7440-57-5, Gold, biological studies 7440-66-6, Zinc, biological studies 7440-69-9, Bismuth, biological studies 7664-93-9, Sulfuric acid, biological studies 9005-65-6, Tween 80 10118-90-8, Minocycline 14320-04-8D, Zinc phthalocyanine, derivs. 19660-77-6, Chlorin e6 25550-58-7, Dinitrophenol 37251-80-2, Toluidine blue 39378-61-5, Bromcresol 51811-82-6, Giemsa's stain 110230-98-3 122341-38-2  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (phototherapy-based method and composition for treating pathogens)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Boyer; US 5189029 A 1993 HCAPLUS
- (2) Hayes, J; US 5464610 A 1995 HCAPLUS
- (3) Lewis; US 5235045 A 1993 HCAPLUS
- (4) Moberg; US 5525635 A 1996 HCAPLUS
- (5) Wohlrab; US 5346692 A 1994 HCAPLUS

IT 69-72-7, Salicylic acid, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (phototherapy-based method and composition for treating pathogens)

RN 69-72-7 HCAPLUS

CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



L39 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1993:66891 HCAPLUS

DN 118:66891

ED Entered STN: 16 Feb 1993

TI Pharmaceutical ointments for treatment of onychomycosis

IN Guo, Yi; Fan, Zhiqin; Guo, Dongmei; et al.

PA Peop. Rep. China

SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 6 pp.

CODEN: CNXXEV

DT Patent

LA Chinese

IC ICM A61K035-78

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1063820	A	19920826	CN 1991-100678	19910130
PRAI CN 1991-100678		19910130		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
CN 1063820	ICM	A61K035-78

AB A pharmaceutical ointment for treating onychomycosis is manufactured consisting of lead oxide mixture 3-5, FeSO<sub>4</sub>·7H<sub>2</sub>O 2-5, alunite 3-5, sublime S 2-4, KAl(SO<sub>4</sub>)<sub>2</sub> 2-4, heated gypsum 2-4, orpiment 2-4, CuCO<sub>3</sub>·Cu (OH)<sub>2</sub> 2-4, cinnabar 1-3, Phellodendron amurense bark 5-5, Stemona japonica 3-5, Impatiens balsamina flower 3-5, Typhonium giganteum tuber 2-4,



Dictamnus dasycarpus root bark 2-4, Angelica dahurica root 2-4, Biota orientalis leaves or young stems 2-4, Burseraceae resin 0.5-7, Commiphora myrrha resin 0.5-4, urea 30-50, lactic acid 1-2, benzoic acid 0.1-0.2, o-hydroxybenzoic acid 5-10, lanolin 15-40, white petrolatum 3-10, beeswax 5-15, and mineral waxes 5-15%. The preps. were clin. tested.

ST onychomycosis ointment salt natural product

IT Angelica dahurica  
 Dictamnus dasycarpus  
 Impatiens balsamina  
 Platycladus orientalis  
 Stemona japonica  
 Typhonium giganteum  
 (pharmaceutical ointments containing, for onychomycosis)

IT Burseraceae  
 Commiphora myrrha  
 (resins, pharmaceutical ointments containing, for onychomycosis)

IT Nail (anatomical)  
 (disease, onychomycosis, treatment of,  
 pharmaceutical ointments containing salts and plant parts for)

IT Pharmaceutical dosage forms  
 (ointments, lead oxide and other substances in, for  
 onychomycosis treatment)


IT Cork tree (Phellodendron)  
 (P. amurense, pharmaceutical ointments containing, for  
 onychomycosis)

IT 50-21-5, Lactic acid, biological studies 57-13-6, Urea, biological studies 65-85-0, Benzoic acid, biological studies 69-72-7, o-Hydroxybenzoic acid, biological studies 1302-91-6, Alunite 1335-25-7, Lead oxide 7704-34-9, Sulfur, biological studies 10124-49-9, Iron sulfate 12069-69-1 12255-89-9, Orpiment 13397-24-5, Gypsum, biological studies 15007-61-1, Potassium aluminum sulfate 19122-79-3, Cinnabar  
 RL: BIOL (Biological study)  
 (pharmaceutical ointments containing, for onychomycosis)

IT 69-72-7, o-Hydroxybenzoic acid, biological studies  
 RL: BIOL (Biological study)  
 (pharmaceutical ointments containing, for onychomycosis)

RN 69-72-7 HCAPLUS

CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



=> b uspatall

FILE 'USPATFULL' ENTERED AT 11:17:54 ON 21 JUL 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:17:54 ON 21 JUL 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs fhitr l44 tot

L44 ANSWER 1 OF 2 USPATFULL on STN

AN 2004:126540 USPATFULL

TI Composition and method for the treatment of onychomycosis in animals

IN Tarbet, Bryon J., Highland, UT, UNITED STATES

PI US 2004096519 A1 20040520

AI US 2003-706708 A1 20031111 (10)

RLI Division of Ser. No. US 2000-545486, filed on 10 Apr 2000, GRANTED, Pat.

Search done by Noble Jarrell


No. US 6680073  
 PRAI US 1999-128604P 19990408 (60)  
 DT Utility  
 FS APPLICATION  
 LREP Kenneth Tarbet, 1652 Seattle Slew Way, Oceanside, CA, 92057  
 CLMN Number of Claims: 26  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 355

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a composition and method for the treatment of white line disease, including ailments such as *onychomycosis*, sporotichosis, hoof rot, jungle rot, pseudallecheria boydii, scopulariopsis or athletes foot. The composition of the present invention is useful for the treatment of fungal infections such as *onychomycosis* in warm blooded animals such as humans and horses. The method of the present invention is directed to the application of a therapeutic amount of the present composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 69-72-7, Salicylic acid, biological studies  
 (solns. for treatment of *onychomycosis* in animals)  
 RN 69-72-7 USPATFULL  
 CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




L44 ANSWER 2 OF 2 USPATFULL on STN  
 AN 2004:14947 USPATFULL  
 TI Composition and method for the treatment of *onychomycosis* in animals  
 IN Tarbet, Bryon J., 11066 N. 5730 W., Highland, UT, United States 84003  
 PI US 6680073 B1 20040120  
 AI US 2000-545486 20000410 (9)  
 PRAI US 1999-128604P 19990408 (60)  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Levy, Neil S.  
 LREP Tarbet, Ken H.  
 CLMN Number of Claims: 12  
 ECL Exemplary Claim: 1  
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
 LN.CNT 266

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a composition and method for the treatment of white line disease, including ailments such as *Onychomycosis*, sporotichosis, hoof rot, jungle rot, pseudallecheria boydii, scopulariopsis or athletes foot. The composition of the present invention is useful for the treatment of fungal infections such as *Onychomycosis* in warm blooded animals such as humans and horses. The method of the present invention is directed to the application of a therapeutic amount of the present composition.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 69-72-7, Salicylic acid, biological studies  
 (solns. for treatment of *onychomycosis* in animals)  
 RN 69-72-7 USPATFULL  
 CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




=> d bib abs hitstr 147 tot

L47 ANSWER 1 OF 3 USPATFULL on STN  
 AN 2004:177913 USPATFULL  
 TI Seborrhic keratosis treatment  
 IN Ancira, Margaret, Phoenix, AZ, UNITED STATES  
 Miller, Mickey, Paradise Valley, AZ, UNITED STATES  
 PI US 2004137077 A1 20040715  
 AI US 2003-684136 A1 20031009 (10)  
 RLI Continuation-in-part of Ser. No. US 2002-72829, filed on 8 Feb 2002,  
 PENDING  
 PRAI US 2001-267978P 20010209 (60)  
 DT Utility  
 FS APPLICATION  
 LREP STINSON MORRISON HECKER LLP, ATTN: PATENT GROUP, 1201 WALNUT STREET,  
 SUITE 2800, KANSAS CITY, MO, 64106-2150  
 CLMN Number of Claims: 79  
 ECL Exemplary Claim: 1  
 DRWN 1 Drawing Page(s)  
 LN.CNT 1505  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The subject of the present invention is seborrhic keratosis removal and  
 prevention utilizing safe dependable effective biocompatible treatments  
 with no scarring, bleeding, burning, freezing, shocking, and  
 hypopigmentation or hyperpigmentation.  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 69-72-7D, Salicylic acid, alkyl derivs.  
 (as melanin inhibitor, composition further containing; seborrhic keratosis  
 treatment using hydrogen peroxide)  
 RN 69-72-7 USPATFULL  
 CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



IT 69-72-7, Salicylic acid, biological studies  
 (composition further containing; seborrhic keratosis treatment using hydrogen  
 peroxide)  
 RN 69-72-7 USPATFULL  
 CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



L47 ANSWER 2 OF 3 USPATFULL on STN  
 AN 2000:91943 USPATFULL  
 TI Phototherapy based method for treating pathogens and composition for


effecting same  
 IN Lurie, Raz, Tel Aviv, Israel  
 PA Dermatolazer Technologies Ltd., Tel Aviv, Israel (non-U.S. corporation)  
 PI US 6090788 20000718  
 AI US 1999-343199 19990630 (9)  
 RLI Continuation of Ser. No. WO 1998-US14162, filed on 13 Jul 1998  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Peselev, Elli  
 LREP Friedman, Mark M.  
 CLMN Number of Claims: 23  
 ECL Exemplary Claim: 1  
 DRWN 2 Drawing Figure(s); 2 Drawing Page(s)  
 LN.CNT 1076

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treating an area of skin or nail affected with a pathogen, the method comprising the step of irradiating the area of skin or nail with a light beam having at least one wavelength absorbable by the pathogen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 69-72-7, Salicylic acid, biological studies  
 (phototherapy-based method and composition for treating pathogens)  
 RN 69-72-7 USPATFULL  
 CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



L47 ANSWER 3 OF 3 USPAT2 on STN  
 AN 2003:120772 USPAT2  
 TI Compositions and methods for enhancing drug delivery across and into epithelial tissues  
 IN Rothbard, Jonathan B., Cupertino, CA, United States  
 Wender, Paul A., Menlo Park, CA, United States  
 McGrane, P. Leo, Mountain View, CA, United States  
 Sista, Lalitha V. S., Sunnyvale, CA, United States  
 Kirschberg, Thorsten A., Mountain View, CA, United States  
 PA Cellgate, Inc., Sunnyvale, CA, United States (U.S. corporation)  
 PI US 6759387 B2 20040706  
 AI US 2002-209421 20020730 (10)  
 RLI Continuation of Ser. No. US 2000-648400, filed on 24 Aug 2000, now patented, Pat. No. US 6593292  
 PRAI US 1999-150510P 19990824 (60)  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Russel, Jeffrey E.  
 LREP Townsend and Townsend and Crew LLP  
 CLMN Number of Claims: 31  
 ECL Exemplary Claim: 1  
 DRWN 41 Drawing Figure(s); 23 Drawing Page(s)  
 LN.CNT 3255  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the


non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length (SEQ ID NO:50).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 69-72-7, Salicylic acid, biological studies  
(compns. and methods for enhancing drug delivery across and into  
epithelial tissues)

RN 69-72-7 USPAT2

CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



=> b home

FILE 'HOME' ENTERED AT 11:18:41 ON 21 JUL 2005

=>